ClinVar Miner

Submissions for variant NM_152618.3(BBS12):c.1063C>T (p.Arg355Ter)

gnomAD frequency: 0.00001  dbSNP: rs121918327
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 12
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000538405 SCV000636538 pathogenic Bardet-Biedl syndrome 2023-09-10 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Arg355*) in the BBS12 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 356 amino acid(s) of the BBS12 protein. This variant is present in population databases (rs121918327, gnomAD 0.006%). This premature translational stop signal has been observed in individual(s) with Bardet-Biedl syndrome (PMID: 17160889, 23591405). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 1147). For these reasons, this variant has been classified as Pathogenic.
Institute Of Human Genetics Munich, Klinikum Rechts Der Isar, Tu München RCV000001206 SCV000680151 pathogenic Bardet-Biedl syndrome 12 2017-09-08 criteria provided, single submitter clinical testing
Centre for Mendelian Genomics, University Medical Centre Ljubljana RCV000626780 SCV000747483 pathogenic Polydactyly, postaxial, type A1; Abnormal cardiovascular system morphology; Visual impairment; Inability to walk 2017-01-01 criteria provided, single submitter clinical testing
Centre for Genomic Medicine, Manchester, Central Manchester University Hospitals RCV000001206 SCV001156389 pathogenic Bardet-Biedl syndrome 12 2019-02-01 criteria provided, single submitter clinical testing
Centre for Mendelian Genomics, University Medical Centre Ljubljana RCV000001206 SCV001370443 pathogenic Bardet-Biedl syndrome 12 2019-03-20 criteria provided, single submitter clinical testing This variant was classified as: Pathogenic. The following ACMG criteria were applied in classifying this variant: PVS1,PM2,PP5.
Fulgent Genetics, Fulgent Genetics RCV000001206 SCV002814272 pathogenic Bardet-Biedl syndrome 12 2022-04-21 criteria provided, single submitter clinical testing
Baylor Genetics RCV000001206 SCV004211673 pathogenic Bardet-Biedl syndrome 12 2023-09-09 criteria provided, single submitter clinical testing
OMIM RCV000001206 SCV000021356 pathogenic Bardet-Biedl syndrome 12 2007-01-01 no assertion criteria provided literature only
Laboratory of Medical Genetics (UMR_S 1112), INSERM/Strasbourg University RCV000538405 SCV000839573 pathogenic Bardet-Biedl syndrome 2018-09-15 no assertion criteria provided provider interpretation
Counsyl RCV000001206 SCV001132342 pathogenic Bardet-Biedl syndrome 12 2017-11-27 no assertion criteria provided clinical testing
Natera, Inc. RCV000001206 SCV001462013 pathogenic Bardet-Biedl syndrome 12 2020-09-16 no assertion criteria provided clinical testing
Advanced Center For Translational And Genetic Medicine, Ann & Robert H. Lurie Children's Hospital Of Chicago RCV003228891 SCV003926581 pathogenic Bardet-Biedl syndrome 1 2023-05-10 no assertion criteria provided research

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.